RxDoctor Payments Data

Peter Headley, MD

Urology · Albuquerque, NMNPI 1134394430

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Astellas Pharma US Inc at 31.0% of the total. Reporting peaked in 2019 at $226 and has fallen 90.0% since, to $23 in 2024. That places this record below the midpoint for urology clinicians in NM, where the typical reported total is $1,519.

$471in general payments, 2019–2025

Across 23 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$146
  • Medtronic$139
  • Sanofi$58
  • Axonics, Inc.$57
  • Ferring Pharmaceuticals Inc.$23
  • Pfizer$19
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$471100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$471 in reported general payments places this provider in the 30th percentile of 46 urology providers in New Mexico.

See all urology providers in New Mexico

Medicare billing

Part B allowed, 2024
$120,908
Medicare patients
319
Services billed
2,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron132$88,822
Tamsulosin Hcl459$11,521
Finasteride187$3,022
Solifenacin Succinate55$2,130
Potassium Citrate ErPotassium Citrate33$1,142
Testosterone Cypionate11$766
Terazosin Hcl12$503
Oxybutynin Chloride ErOxybutynin Chloride24$446
Doxazosin Mesylate17$407
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen43$276
Oxybutynin Chloride16$207
Tadalafil12$179
Chlorthalidone11$124
Ciprofloxacin Hcl22$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$146$88,822132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 46 urology providers in New Mexico.

Other urology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →